Bruker (NASDAQ:BRKR) PT Lowered to $80.00

Bruker (NASDAQ:BRKR) had its target price cut by research analysts at Citigroup from $95.00 to $80.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Citigroup’s target price points to a potential upside of 25.55% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Bruker in a report on Monday, June 3rd. They set a “buy” rating and a $85.00 price target on the stock. Bank of America dropped their price objective on shares of Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Monday, May 20th. The Goldman Sachs Group dropped their price objective on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday. StockNews.com downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. Finally, Stifel Nicolaus dropped their price objective on shares of Bruker from $81.00 to $77.00 and set a “hold” rating on the stock in a report on Monday, May 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.78.

Bruker Stock Up 4.0 %

Shares of Bruker stock opened at $63.72 on Wednesday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The company has a 50-day moving average of $68.43 and a 200 day moving average of $76.67. The firm has a market cap of $9.26 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 2.10 and a beta of 1.20. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. The company had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. Bruker’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. As a group, sell-side analysts anticipate that Bruker will post 2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bruker

Several institutional investors and hedge funds have recently modified their holdings of BRKR. Lindbrook Capital LLC grew its holdings in shares of Bruker by 68.2% in the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 146 shares in the last quarter. Rise Advisors LLC purchased a new position in shares of Bruker in the first quarter valued at $27,000. Neo Ivy Capital Management purchased a new position in shares of Bruker in the fourth quarter valued at $30,000. VisionPoint Advisory Group LLC grew its holdings in shares of Bruker by 145.0% in the third quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 303 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of Bruker in the fourth quarter valued at $33,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.